(Photo: Cheryl Gerber/AP) |
The company said it expects to have a result from the trials by early next year, which could lead to government authorization of the vaccine for emergency use soon afterwards.
Johnson & Johnson is collaborating with the UK on a separate phase-3 clinical trial that will test a two-dose regimen of the vaccine in multiple countries.